In this study, a significant decline in NfL levels under nusinersen treatment was found only for patients with SMA type I. The decrease in pNfH levels was observed for both SMA type I and SMA type II pediatric patients [214]. Here, NEFL is linked to spinal muscular atrophy, type 1.